Go to the list of all blogs
Serhii Bondarenko's Avatar
published in Blogs
Oct 02, 2026
DOXGX: Dodge & Cox Stock Fund Navigates Recent Consolidation

DOXGX: Dodge & Cox Stock Fund Navigates Recent Consolidation

Key Takeaways

  • DOXGX, the Dodge & Cox Stock Fund Class X, is an actively managed large-value U.S. equity mutual fund with a net expense ratio of 0.41%.
  • The fund's NAV declined roughly 6% over the trailing 30 days, from about $18.25 to $17.13, after peaking near $18.50 in mid-August.
  • The fund ended the third quarter essentially flat, with the recent pullback erasing most of its summer gains.
  • Performance reflects a value-oriented portfolio weighted toward healthcare, financials, and industrials rather than mega-cap growth.
  • Key holdings include Charles Schwab, RTX, Johnson Controls, Occidental Petroleum, and Taiwan Semiconductor.

Market Snapshot and Recent Price Action

DOXGX has moved into a consolidation phase following its mid-summer advance. The net asset value climbed to roughly $18.50 in mid-August before easing lower through September and settling near $17.13 on the latest pricing. That amounts to a decline of about 6% over the past 30 days, keeping the fund inside its typical large-value trading range rather than marking any sharp reversal.

As a large-value strategy, DOXGX often diverges from the broad market when growth and mega-cap technology names dominate. Its lower beta and emphasis on financials, healthcare, and industrials mean results tend to track the fortunes of economically sensitive and dividend-focused companies. The latest pullback aligns with that value tilt giving back some earlier gains as sector leadership shifted.

Fund Overview and Positioning

The Dodge & Cox Stock Fund has operated as an actively managed U.S. equity strategy since 1965, with the Class X shares (DOXGX) launching in May 2022. It allocates at least 80% of assets to equities in established medium-to-large companies viewed as undervalued relative to long-term earnings potential, allowing up to 20% in non-U.S. issuers.

Management follows a collaborative committee process grounded in fundamental research. Sector weights center on healthcare at around 25%, financials near 18%, technology about 14%, and industrials roughly 13%, with communication services and energy also prominent. Leading positions have featured SCHW, RTX, JCI, OXY, and TSM. The 0.41% expense ratio, no-load structure, and experienced team stand out as advantages in the large-value space. I also checked this using Tickeron’s AI Screener to see how the fund compares to peers in the category.

Drivers Behind the Recent Move

Because DOXGX is a diversified mutual fund, its NAV changes reflect the aggregate results of its holdings and the overall market backdrop more than any single corporate development. The fund rose steadily through July and into early August, pushing the NAV toward the $18.50 level, before the late-summer decline brought it back below $17.50 in September.

Structural elements help explain the pattern. The value focus leaves the portfolio heavily exposed to names such as Charles Schwab and MetLife in financials, CVS Health and Gilead Sciences in healthcare, and Occidental Petroleum in energy. When investor preference shifts toward cyclical and value stocks less than large-cap growth, the fund can trail the broader index. The September softening, while contained, highlights how a concentrated value approach can react to changes in sector sentiment and rate expectations. From what I see, this sensitivity remains a core characteristic worth monitoring.

Looking Ahead to 2026

Several elements should influence DOXGX performance through 2026. Interest-rate paths and inflation expectations will likely matter most, given that value and financially oriented holdings often respond more directly to rate shifts than growth equities. Attention to the heaviest sector exposures—especially healthcare and financials—will also be key, as earnings trends and regulatory moves can affect the largest positions.

At the portfolio level, results from top holdings such as RTX, TSM, and FedEx will matter, along with any re-emergence of value leadership versus mega-cap growth. The fund’s committee-driven process and low turnover point to limited strategy drift, though short-term NAV fluctuations will still follow its concentrated value book. Distributions and broader market volatility remain additional factors for shareholders.

Exploring Tickeron AI Tools

One resource I’ve turned to for additional perspective is Tickeron’s Trending AI Robots page. It highlights a selection of the platform’s stronger-performing automated strategies filtered for relevance and recent results. These bots span different approaches and timeframes, giving investors a practical way to review systematic signals alongside their own analysis of funds like DOXGX.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: DOXGX

Contributor

Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.


Industry description

The investment seeks long-term growth of principal and income; a secondary objective is to achieve a reasonable current income. The fund invests primarily in a diversified portfolio of equity securities. It will invest at least 80% of its total assets in equity securities, including common stocks, depositary receipts evidencing ownership of common stocks, certain preferred stocks, securities convertible into common stocks, and securities that carry the right to buy common stocks. The fund may invest up to 20% of its total assets in securities of non-U.S. issuers that are not in the S&P 500 Index.
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Category LargeValue

Category
Large Value
Address
Dodge & Cox Funds40 Th FloorSan Francisco
Phone
1-800-621-3979
Web
www.dodgeandcox.com
Interact to see
Advertisement
Shares of Viridian Therapeutics (VRDN) are down approximately 32% in premarket trading on March 30, 2026, against a prior closing price of $27.39 on March 27, 2026, implying a premarket price near $18.63. The primary catalyst is the release of topline Phase 3 REVEAL-1 clinical trial data for elegrobart (VRDN-003) in patients with active thyroid eye disease (TED), long anticipated as the company's most critical near-term de-risking event.
SYY shares are trading approximately -6.40% lower in premarket trading on March 30, 2026, from a prior close of $81.80 to roughly $76.56. The primary catalyst is Sysco's announcement of a $29.1 billion definitive agreement to acquire Jetro Restaurant Depot, one of the nation's largest Cash & Carry food wholesalers.
Northwest Biotherapeutics, Inc. (NWBO) is a clinical-stage biotechnology company focused on developing personalized immune therapies, primarily dendritic cell-based vaccines under its DCVax platform. The company's lead candidate, DCVax-L, targets glioblastoma multiforme (GBM), a lethal brain cancer, following completion of a Phase III trial. DCVax-Direct addresses inoperable solid tumors, with Phase I/II data available. NWBO operates in the competitive immunotherapy sector against players like large-cap biotechs, relying on a proprietary manufacturing process for cost-effective production.
FingerMotion, Inc. (FNGR) operates as a mobile data specialist, delivering mobile payment and recharge platform solutions mainly in China. The company's core revolves around telecommunication products and services, such as top-up recharges, data plans, SMS and MMS services, big data insights for consumer behavior analysis, and rich communication services (RCS) platforms. It also provides value-added products through partnerships with telecom providers and e-commerce platforms.
NIO Inc. (NIO) stands out as a leading Chinese electric vehicle manufacturer focused on premium smart EVs. The company designs, develops, and sells high-end battery electric vehicles, bolstered by its Battery-as-a-Service model that lets customers swap batteries at stations rather than owning them. In the cutthroat Chinese EV space, NIO competes directly with firms like XPEV and LI.
Xcel Energy Inc. (XEL) stands out as a major U.S. electric and natural gas utility, serving about 3.7 million electric and 2.2 million natural gas customers across eight states, mainly in the Midwest and West. The company focuses on regulated utilities, handling electricity generation, transmission, and distribution, while increasingly prioritizing renewable sources like wind and solar. Its model centers on steady, regulated returns from infrastructure investments, backed by rate cases and recovery mechanisms.
Occidental Petroleum Corporation (OXY) stands out as a leading independent energy producer, with a primary focus on hydrocarbon exploration and production. The company has significant operations in the Permian Basin, one of the U.S.'s most productive oil regions, along with assets in the Rockies, Latin America, and the Middle East. Its business model emphasizes efficient drilling, low-cost production, and carbon capture initiatives aimed at long-term sustainability.
The ProShares UltraShort Bloomberg Natural Gas (KOLD) is a leveraged inverse exchange-traded fund that seeks daily investment results, before fees and expenses, corresponding to two times the inverse (-2x) of the daily performance of the Bloomberg Natural Gas Subindex. This subindex reflects the natural gas segment of the commodities market by tracking futures contracts, primarily the second-month Henry Hub natural gas futures, weighted by liquidity and production. The fund does not invest directly in physical natural gas but uses derivatives like futures contracts and swaps to achieve its objective.
Shares of United Therapeutics (UTHR) are surging approximately +17% in premarket trading on Monday, March 30, 2026, with the market not yet open. The primary catalyst is a landmark Phase 3 clinical trial announcement: the TETON-1 pivotal study of nebulized Tyvaso® (treprostinil) met its primary endpoint for treating idiopathic pulmonary fibrosis (IPF), exceeding the already impressive treatment effects seen in the previously completed TETON-2 study.
AA shares are surging approximately +11.79% intraday on Monday, March 30, 2026, trading around $64.55 versus Friday's close of approximately $57.74. The primary catalyst is a supply shock in the global aluminum market: two major Middle Eastern aluminum producers — including Bahrain's Aluminium Bahrain (ALBA) — reported being struck by Iranian attacks, raising fears of significant output disruptions.
BSX shares are falling approximately 7.00% during Monday's session, trading near $64.33, down from Friday's close of $69.17. Primary catalyst: A "sell the news" reaction to Saturday's CHAMPION-AF clinical trial data for the WATCHMAN FLX™ device — results met all endpoints but contained meaningful caveats that are spooking investors.
Shares of CIEN are declining approximately -7.00% in Monday's session, with the stock trading near $369.68, versus a prior close of $397.50 on Friday, March 27, 2026. The primary catalyst is a broad, tariff-driven market sell-off as the Trump administration's escalating trade posture rattles investor sentiment across the technology and networking sectors heading into quarter-end.
Bloom Energy (BE) shares are trading down approximately 8.00% intraday on Monday, March 30, 2026, falling from a prior close of $133.24 to around $122.58, extending a turbulent stretch for the stock. The decline is driven by a confluence of broad macro selling pressure, renewed concerns around AI data center demand durability, and investor uncertainty following a CFO transition announced on Friday.
AAOI shares are trading down approximately 10.00% intraday on Monday, March 30, falling from a prior close of $98.21 to around $88.39. A broad-based market sell-off fueled by renewed tariff fears and macro uncertainty is putting acute pressure on technology and semiconductor-linked stocks.
In recent trading sessions, I've been watching the GraniteShares 2x Long DELL Daily ETF (DLLL) closely, as it shows heightened volatility that mirrors amplified movements in its underlying asset, Dell Technologies (DELL). From what I see, the ETF's performance reflects robust demand for AI-optimized servers and infrastructure solutions, propelling gains during periods of positive sentiment around DELL's earnings and strategic positioning. Recent weeks have seen sharp intraday swings, underscoring the leveraged nature of DLLL, which seeks 2x daily exposure before fees. Trading volumes have surged alongside broader interest in AI-related plays, though the ETF remains suitable primarily for short-term tactical positioning amid ongoing market cycles in technology hardware.
Planet Labs PBC (PL) shares fell 4.75% in the most recent completed session, closing at $30.86 versus a prior close of $32.40. Premarket indications today show PL down further, with quotes around $30.53–31.35, roughly 1–2% below Friday’s close, after having traded down as much as about 9% intraday last week.
SUNation Energy Inc. (SUNE) is indicated down about 19% in Monday’s premarket session after previously closing just under the mid‑$2 range in recent trading. The drop follows an exceptionally volatile March in which SUNE shares repeatedly surged on technical breakouts and debt‑restructuring news, including single‑day gains of 19–26%.
Micron Technology, Inc. (MU) fell 5.71% in the most recent completed session, dropping from a prior close of $357.21 to $336.84. The decline extends a pullback that began after MU’s post‑earnings surge in mid‑March, when the shares traded near a 52‑week high above $470 before sliding roughly 24–30% over subsequent sessions.
Karman Holdings Inc. (KRMN) fell 5.38% in the most recent completed session, closing at $84.07 after trading between $83.43 and $88.98. The pullback comes after a powerful multi‑month rally that saw the stock climb from a 52‑week low of about $25.02 to a high of $118.38, leaving it vulnerable to profit‑taking and valuation compression.
Lumentum Holdings Inc. (LITE) shares fell 4.93% in the most recent completed session, sliding from a prior close of $702.75 to $668.10. The drop comes after a massive AI-driven rally that pushed LITE up more than 1,000% over the past year and more than doubled year to date, leaving valuations stretched and vulnerable to profit‑taking.